Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)

Dexlansoprazole Injection

Dexmedetomidine

Dexmedetomidine

Digoxin

Eprolidone

Esketamine injection group (0.25 mg/kg)

Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））

FT-003

FT-003

Ferric Carboxymaltose Injection

First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers

First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

First-in-Human Study of RO7812653

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

First-in-Human trial of DS9051b in participants with advanced solid tumors

First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Frequently asked questions